Paolo Tarantino, Research Fellow at Dana-Farber Cancer Institute, shared a post on X:
“CDK4/6 inhibitor rechallenge/switch: should we? Positive data from postMONARCH, though with only a small (<1 mo) PFS advantage, and EMBER-3 suggesting a greater PFS advantage with imlunestrant/abema (not yet approved). Controversy remains.”
